p53-Mdm2 binding inhibitors (Priaxon/NexusPharma/Boehringer)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug Namep53-Mdm2 binding inhibitors (Priaxon/NexusPharma/Boehringer)
Drug Alias Namep53-Mdm2 binding inhibitors (Priaxon/NexusPharma)Mdm2 inhibitors (Priaxon/NexusPharma)BI-MDM2GBM-14NXN-11 +[10] 
ClassificationSmall molecules
Mechanisms of Actionp53-binding protein Mdm-2 inhibitorsTumor protein p53 inhibitors
Targetsp53-binding protein Mdm-2Tumor protein p53
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermany
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesNexus Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesNexus Pharmaceuticals IncBoehringer Ingelheim International GmbhPriaxon Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A